GT Biopharma, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
GT Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • GT Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$3.41M, a 41.2% decline year-over-year.
  • GT Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$12.3M, a 20.8% decline year-over-year.
  • GT Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7.6M, a 63.6% increase from 2022.
  • GT Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$20.9M, a 64% increase from 2021.
  • GT Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$58M, a 105% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$12.3M -$3.41M -$995K -41.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$11.4M -$3.71M -$1.72M -86.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$9.64M -$2.27M -$2.04M -898% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$7.6M -$2.96M +$2.62M +47% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 -$10.2M -$2.42M +$4.47M +64.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$14.7M -$1.99M +$987K +33.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$15.7M -$227K +$5.21M +95.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$20.9M -$5.58M +$12.4M +69% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 -$33.3M -$6.88M -$1.43M -26.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$31.9M -$2.98M +$1.88M +38.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$33.8M -$5.44M +$24.2M +81.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$58M -$18M -$11.7M -187% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$46.3M -$5.45M -$2.58M -89.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-31
Q2 2021 -$43.7M -$4.86M +$12.6M +72.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$56.3M -$29.7M -$28M -1638% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$28.3M -$6.29M -$4.82M -328% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 -$23.5M -$2.88M +$27M +90.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$50.5M -$17.4M -$14.6M -525% Apr 1, 2020 Jun 30, 2020 10-Q/A 2021-12-29
Q1 2020 -$35.8M -$1.71M +$2.8M +62.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$38.6M -$1.47M +$2.76M +65.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-04-16
Q3 2019 -$41.4M -$29.9M +$206M +87.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$247M -$2.79M +$6.29M +69.3% Apr 1, 2019 Jun 30, 2019 10-Q/A 2020-08-18
Q1 2019 -$254M -$4.51M +$5.58M +55.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 -$259M -$4.23M +$1.8M +29.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-27
Q3 2018 -$261M -$236M -$105M -80.5% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$156M -$9.08M -$6.62M -269% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$149M -$10.1M -$5.03M -99.5% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 -$144M -$6.03M -$3.2M -113% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-29
Q3 2017 -$141M -$131M -$127M -3498% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 -$14M -$2.46M -$4.01M -260% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$9.97M -$5.06M -$19.7M -134% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 $9.77M -$2.83M +$23.3M +89.2% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$13.5M -$3.63M -$1.94M -115% Jul 1, 2016 Sep 30, 2016 10-Q/A 2018-02-28
Q2 2016 -$11.6M $1.54M -$25.3M -94.3% Apr 1, 2016 Jun 30, 2016 10-Q/A 2018-02-28
Q1 2016 $13.7M $14.7M +$35.2M Jan 1, 2016 Mar 31, 2016 10-Q/A 2018-02-28
Q4 2015 -$21.5M -$26.1M -$7.48M -40.1% Oct 1, 2015 Dec 31, 2015 10-K/A 2018-02-28
Q3 2015 -$14M -$1.69M +$2.53M +59.9% Jul 1, 2015 Sep 30, 2015 10-Q/A 2018-02-28
Q2 2015 -$16.5M $26.9M +$27.1M Apr 1, 2015 Jun 30, 2015 10-Q/A 2018-02-28
Q1 2015 -$43.6M -$20.5M -$20.1M -5430% Jan 1, 2015 Mar 31, 2015 10-Q/A 2018-02-28
Q4 2014 -$23.5M -$18.6M -$18.3M -5530% Oct 1, 2014 Dec 31, 2014 10-K/A 2018-02-28
Q3 2014 -$5.18M -$4.22M -$3.9M -1223% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-13
Q2 2014 -$1.28M -$262K +$57K +17.9% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-14
Q1 2014 -$1.34M -$371K -$839K -179% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-14
Q4 2013 -$501K -$331K +$430K +56.5% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-31
Q3 2013 -$931K -$319K +$1.08M +77.2% Jul 1, 2013 Sep 30, 2013 10-Q 2014-12-17
Q2 2013 -$2.01M -$319K +$2.08M +86.7% Apr 1, 2013 Jun 30, 2013 10-Q 2015-01-08
Q1 2013 -$4.09M $468K +$1.08M Jan 1, 2013 Mar 31, 2013 10-Q 2015-01-08
Q4 2012 -$5.17M -$761K +$377K +33.1% Oct 1, 2012 Dec 31, 2012 10-K 2015-01-08
Q3 2012 -$5.55M -$1.4M -$1.42M -6187% Jul 1, 2012 Sep 30, 2012 10-Q 2014-12-17
Q2 2012 -$4.13M -$2.4M -$1.73M -262% Apr 1, 2012 Jun 30, 2012 10-Q 2014-12-12
Q1 2012 -$2.39M -$615K +$1.31M +68% Jan 1, 2012 Mar 31, 2012 10-Q 2014-12-10
Q4 2011 -$3.7M -$1.14M Oct 1, 2011 Dec 31, 2011 10-K 2014-11-18
Q3 2011 $23K +$656K Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-21
Q2 2011 -$662K -$1.06M -266% Apr 1, 2011 Jun 30, 2011 10-Q/A 2012-09-13
Q1 2011 -$1.92M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-21
Q3 2010 -$633K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-21
Q2 2010 $399K Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-09-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.